cIMT, μm
|
650 ± 140
|
740 ± 140
|
0.000
| |
Age, years
|
54 ± 14
|
62 ± 9
|
0.000
| |
Female, n (%)
|
531 (78)
|
437 (76)
|
0.40
| |
BMI, kg/m2
|
27 ± 6
|
28 ± 5
|
0.39
| |
Abdominal circumference, cm
|
94 ± 15
|
94 ± 14
|
0.92
| |
Cardiovascular data
|
CV risk factors, n (%)
|
Current smoker
|
169 (25)
|
153 (26)
|
0.47
| |
Obesity
|
193 (28)
|
155 (27)
|
0.58
| |
Dyslipidemia
|
275 (40)
|
332 (57)
|
0.000
| |
Hypertension
|
192 (28)
|
271 (47)
|
0.000
| |
Blood pressure, mmHg
|
Systolic
|
130 ± 18
|
132 ± 16
|
0.024
| |
Diastolic
|
78 ± 10
|
79 ± 9
|
0.58
| |
Lipids
|
Total cholesterol, mmol/l
|
5.26 ± 0.96
|
5.28 ± 0.96
|
0.66
| |
Triglycerides, mmol/l
|
1.24 ± 0.71
|
1.28 ± 0.68
|
0.35
| |
HDL cholesterol, mmol/l
|
1.58 ± 0.44
|
1.58 ± 0.44
|
0.90
| |
LDL cholesterol, mmol/l
|
3.10 ± 0.80
|
3.10 ± 0.83
|
0.94
| |
Atherogenic index
|
3.56 ± 1.11
|
3.53 ± 0.97
|
0.63
| |
Statins, n (%)
|
113 (17)
|
188 (33)
|
0.000
| |
Aspirin, n (%)
|
16 (2)
|
27 (5)
|
0.018
| |
Antihypertensive treatment, n (%)
|
140 (20)
|
190 (33)
|
0.000
| |
Disease-related data
|
Disease duration, years
|
5 (2–12)
|
5 (2–12)
|
0.62
| |
CRP at time of study, mg/l
|
2.5 (0.9–6.4)
|
3.0 (1.0–7.0)
|
0.71
| |
ESR at time of study, mm/ 1° hour
|
11 (5 − 21)
|
13 (6–25)
|
0.007
|
1.00 (0.99–1.01), 0.79
|
Rheumatoid factor, n (%)
|
380 (56)
|
360 (62)
|
0.019
|
1.58 (1.19–2.11), 0.002
|
ACPA, n (%)
|
352 (51)
|
320 (55)
|
0.097
|
1.46 (1.09–1.94), 0.011
|
DAS28-ESR
|
2.96 ± 1.50
|
3.27 ± 1.46
|
0.000
|
1.09 (1.02–1.19), 0.028
|
DAS28-PCR
|
2.91 ± 1.28
|
3.10 ± 1.28
|
0.010
|
1.04 (0.93–1.16), 0.095
|
SDAI
|
3.20 ± 2.05
|
3.10 ± 2.02
|
0.73
| |
CDAI
|
8 (3–16)
|
9 (4–17)
|
0.078
|
1.00 (0.99–1.02), 0.52
|
HAQ
|
0.690 (0250–1.250)
|
0.750 (0250–1.250)
|
0.36
| |
RAPID
|
3.20 ± 2.05
|
3.10 ± 2.02
|
0.61
| |
Current drugs, n (%)
|
Prednisone
|
330 (48)
|
291 (50)
|
0.46
| |
Prednisone doses, mg/day
|
5 (2.5–6)
|
5 (5–7.5)
|
0.42
| |
NSAIDs
|
282 (41)
|
205 (35)
|
0.036
|
0.93 (0.70–1.24), 0.62
|
DMARDs
|
525 (77)
|
444 (77)
|
0.98
| |
Methotrexate
|
395 (58)
|
324 (56)
|
0.55
| |
Leflunomide
|
70 (10)
|
68 (12)
|
0.39
| |
Hydroxychloroquine
|
147 (21)
|
132 (23)
|
0.57
| |
Sulphasalazine
|
19 (3)
|
24 (4)
|
0.18
|
1.69 (0.84–3.41), 0.15
|
Anti-TNF therapy
|
91 (13)
|
72 (12)
|
0.66
| |
Adalimumab
|
26 (4)
|
28 (5)
|
0.36
| |
Infliximab
|
12 (2)
|
6 (1)
|
0.29
| |
Etanercept
|
40 (6)
|
26 (4)
|
0.28
| |
Golimumab
|
1 (0)
|
3 (1)
|
0.34
| |
Tocilizumab
|
37 (5)
|
27 (5)
|
0.56
| |
Rituximab
|
9 (1)
|
11 (2)
|
0.40
| |
Abatacept
|
8 (1)
|
13 (2)
|
0.14
|
2.13 (0.77–5.97), 0.15
|
Baricitinib
|
5 (1)
|
6 (1)
|
0.56
| |
Tofacitinib
|
9 (1)
|
5 (1)
|
0.45
| |
Historical disease-related data
|
History of extraarticular manif., n (%)
|
112 (16)
|
119 (21)
|
0.058
|
1.07 (0.75–1.52), 0.72
|
Erosions, n (%)
|
230 (34)
|
216 (37)
|
0.048
|
1.26 (0.93–1.72), 0.13
|
CRP at time of disease diagnosis, mg/l
|
7 (2–19)
|
8 (3–22)
|
0.28
| |
CRP > 3 at time of diagnosis, n (%)
|
354 (52)
|
324 (56)
|
0.068
|
1.13 (0.78–1.64), 0.52
|
ESR at the time of diagnosis, mm/1st hour
|
20 (11–37)
|
23 (12–40)
|
0.28
| |